Skip to search formSkip to main contentSkip to account menu

SPD754

Known as: AVX-754, AVX754, SPD 754 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apricitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection
ABSTRACT SPD754 (AVX754) is a deoxycytidine analogue nucleotide reverse transcriptase inhibitor (NRTI) in clinical development… 
2006
2006
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
Objective:Apricitabine (formerly AVX754 and SPD754) is a deoxycytidine analogue nucleoside reverse transcriptase inhibitor in… 
2005
2005
In Vitro Activity of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor (NRTI), against 215 HIV-1 Isolates Resistant to Other NRTIs
SPD754 (also known as AVX-754) is a deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with antiretroviral… 
2004
2004
New HIV Drug Class : ‘ Entry Inhibitors ’ Which Block HIV from Entering CD 4 Cell
IN THIS ISSUE: Tipranavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 HIV Entry Inhibitors… 
Review
2004
Review
2004
New antiretroviral agents for the treatment of HIV infection
Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current… 
2004
2004
New antiretroviral agents for the treatment of HIV infection
Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)